SECUKINUMAB DEMONSTRATES CONSISTENT SAFETY OVER LONG-TERM EXPOSURE (UP TO 3 YEARS) IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES

被引：0
|
作者：
Deodhar, A. [1 ]
Baraliakos, X. [2 ]
Marzo-Ortega, H. [3 ,4 ]
Sieper, J. [5 ]
Gupta, A. D. [6 ]
Porter, B. [7 ]
Fox, T. [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Ruhr Univ Bochum, Bochum, Germany
[3] Univ Leeds, Leeds Teaching Hosp Trust, Leeds, W Yorkshire, England
[4] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[5] Charite, Berlin, Germany
[6] Novartis Healthcare, Hyderabad, India
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
174
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [41] LONG-TERM OUTCOME OF PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS WITH ETANERCEPT - SUSTAINED EFFICACY AND SAFETY AFTER 7 YEARS
    Baraliakos, X.
    Haibel, H.
    Fritz, C.
    Listing, J.
    Heldmann, F.
    Braun, J.
    Sieper, J.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 638 - 638
  • [42] Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies (vol 20, pg 589, 2017)
    Wei, J. C. C.
    Baeten, D.
    Sieper, J.
    Deodhar, A.
    Bhosekar, V
    Martin, R.
    Porter, B.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2017, 20 (07) : 911 - 911
  • [43] Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    Brandt, J
    Listing, J
    Haibel, H
    Sörensen, H
    Schwebig, A
    Rudwaleit, M
    Sieper, J
    Braun, J
    RHEUMATOLOGY, 2005, 44 (03) : 342 - 348
  • [44] Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial
    Baraliakos, X.
    Kivitz, J.
    Deodhar, A. A.
    Braun, J.
    Wei, J. C.
    Delicha, E. M.
    Talloczy, Z.
    Porter, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (01) : 50 - 55
  • [45] LONG-TERM RETENTION, EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS OR ANKYLOSING SPONDYLITIS: RESULTS FROM THE OBSERVATIONAL SERENA STUDY
    Kiltz, U.
    Sfikakis, P.
    Gullick, N.
    Katsimpri, P.
    Kotrotsios, A.
    Brandt-Juergens, J.
    Lespessailles, E.
    Maiden, N.
    Gaffney, K.
    Peterlik, D.
    Schulz, B.
    Pournara, E.
    Jagiello, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 846 - 847
  • [46] Impact of Weight and Sex on Long-term Persistence to Secukinumab Treatment in Patients with Active Psoriatic Arthritis or Ankylosing Spondylitis
    Kiltz, Uta
    Sfikakis, Petros P.
    Gullick, Nicola
    Theodoridou, Athina
    Kandyli, Anna
    Brandt-Juergens, Jan
    Goupille, Philippe
    Maiden, Nicola
    Gaffney, Karl
    Peterlik, Daniel
    Schulz, Barbara
    Pournara, Effie
    Jagiello, Piotr
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2067 - 2069
  • [47] SAFETY AND TOLERABILITY OF SECUKINUMAB OVER LONG-TERM EXPOSURE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA) AND MODERATE TO SEVERE PLAQUE PSORIASIS (PSO): UPDATED POOLED SAFETY ANALYSES
    Bird, P.
    Mease, P.
    McInnes, I.
    Reich, K.
    Andersson, M.
    Tao, A.
    Fox, T.
    Karyekar, C.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 38 - 38
  • [48] Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
    Griffiths, Christopher
    Reich, Kristian
    Leonard, Craig
    Blauvelt, Andrew
    Mehta, Nehal
    Tsai, Tsen-Fang
    Gong, Yankun
    Huang, Jiaqing
    Fox, Todd
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S14 - S14
  • [49] Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
    Baraliakos, Xenofon
    Haibel, Hildrun
    Fritz, Claudia
    Listing, Joachim
    Heldmann, Frank
    Braun, Juergen
    Sieper, Joachim
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (03)
  • [50] Secukinumab demonstrates an acceptable safety profile in moderate to severe plaque psoriasis: Pooled analysis of 10 phase 2/3 studies
    Foley, P.
    Griffiths, C.
    Reich, K.
    Leonardi, C. L.
    Blauvelt, A.
    Mehta, N. N.
    Tsai, T. F.
    Gong, Y.
    Papavassilis, C.
    Huang, J.
    Fox, T.
    van de Kerkhof, P.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 50 - 50
12345